Search results for: 'same disorders partnering 2025 2019'

Psychiatry Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2019 to 2025

Metabolic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2019 to 2025

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals

Global Biotech Partnering Terms and Agreements 2018 to 2023 report provides a detailed understanding and analysis of how and why companies enter biotech partnering deals.

Specialty Pharmaceutical Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals. 

Academic and Non-Profit Partnering Terms and Agreements 2021-2026 provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. 

The Leading Partnering Intelligence Platform for Pharma, Biotech and Diagnostic Dealmakers

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report offers in-depth insights and exclusive access to clinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2026) report offers in-depth insights and exclusive access to preclinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.

Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2026 report provides a detailed understanding and analysis of how and why companies enter generic pharmaceutical partnering deals.